Hutchmed

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Hutchmed sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).

17 total trials 2 currently recruiting 8 completed early-phase tilt top decile by trial count

Hutchmed: 17 sponsored US clinical trials, 2 recruiting.

Hutchmed sponsors 17 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 8 completed. 0 of these trials are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Tumors, with 1 trials.

Top-decile sponsor footprint

Hutchmed ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

8 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (53.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

17 total, page 1 of 1

RECRUITING Phase 1

HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor

NCT07396584
RECRUITING Phase 1

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

NCT07228247
COMPLETED Phase 1

HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study

NCT05720767
COMPLETED Phase 1

HMPL-523 Food Effect and Proton Pump Inhibitor Study

NCT05571787
COMPLETED Phase 1

HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI

NCT05602597
COMPLETED Phase 1

Fruquintinib Renal Impairment Study

NCT05216354
COMPLETED Phase 1

Fruquintinib Hepatic Impairment Study

NCT05216367
COMPLETED Phase 1

Fruquintinib DDI Study With P-gp and BCRP Substrates

NCT05368805
COMPLETED Phase 1

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

NCT05093322
TERMINATED Phase 2

Open-Label Surufatinib in European Patients With NET

NCT04579679
TERMINATED Phase 1

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

NCT04577963
TERMINATED Phase 1

A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

NCT04764474
TERMINATED Phase 1

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

NCT04579757
TERMINATED Phase 1

A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations

NCT04762602
TERMINATED Phase 1

An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

NCT03779113
TERMINATED Phase 1

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

NCT03786926
COMPLETED Phase 1

A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

NCT02549937

Phase Distribution

PhaseTrial count
Phase 1 16
Phase 2 1

Therapeutic Areas

Tumors 1
Solid Tumors, Adult 1
Renal Impairment 1

What is open in the Hutchmed pipeline

2 recruiting of 17 indexed (12% open); 8 completed (47%).

Phase mix: 0 late (III/IV) vs 17 early (I/II) (early-phase heavy).

Top condition: Tumors (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Hutchmed: open-pipeline peers nationwide

Peers matched on 17 registered trials and 12% open enrollment, not the therapeutic-area sidebar.

Hutchmed sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1520253035 0%5%10%15%20%25% Total trials Recruiting share HutchmedAchieve Life SciencesBioDelivery Sciences InternationalChugai PharmaceuticalConvaTecCochlearErchonia CorporationInternational Maternal Pediatric Adolescent AIDS Clinical Trials GroupPrECOG
Hutchmed sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Hutchmed sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 17 trials (± recruiting share)

Sponsors near 12% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Hutchmed page

17 registered trials is a research-attention snapshot, not an endorsement of Hutchmed or any single study.

  • 2 of Hutchmed's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Tumors is the condition Hutchmed studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Tumors trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Hutchmed pipeline card: 17 registered trials from official public datasets.Report a data error.